COMPANY PROFILE / #370
Enveda
Developer of an artificial intelligence-powered drug discovery platform designed to decode nature's chemical code. The company offers a searchable library of plant-derived molecules, foundation models for natural chemistry, an automated laboratory for high-throughput screening, proprietary large language models for chemical structure prediction, mass spectrometry-driven natural product discovery, and database linking thirty-eight thousand plants to twelve thousand human diseases, enabling scientists to identify therapeutic properties of natural molecules and accelerate the development of life-saving medicines.Privately Held (backing)
已融资383
最新估值—
员工数—
成立年份HotSpot Therapeutics, Terra Lumina, Atavistik Bio, Montai Therapeutics, Cullgen, Pangea Bio, Nurix Therapeutics, Jounce Therapeutics, Progenra, Cantex Pharmaceuticals, Exscientia, Kymera Therapeutics, Silverback Therapeutics, Relay Therapeutics, Recursion Pharmaceuticals, Plexium, Numerion Labs, Phenomic AI, insitro, NexImmune, Genetix Biotherapeutics, Beactica Therapeutics, ImmunoGenesis, Kronos Bio, CHARM Therapeutics, Citryll, PlantForm, Cedilla Therapeutics, Brightseed, Valence Labs, Schrodinger, ChemAxon, InSilico Medicine Cayman
公司概况
- Companies
- Enveda
- Description
- —
- Website
- Boulder, CO
- HQ Location
- Developer of an artificial intelligence-powered drug discovery platform designed to decode nature's chemical code. The company offers a searchable library of plant-derived molecules, foundation models for natural chemistry, an automated laboratory for high-throughput screening, proprietary large language models for chemical structure prediction, mass spectrometry-driven natural product discovery, and database linking thirty-eight thousand plants to twelve thousand human diseases, enabling scientists to identify therapeutic properties of natural molecules and accelerate the development of life-saving medicines.
- Year Founded
- HotSpot Therapeutics, Terra Lumina, Atavistik Bio, Montai Therapeutics, Cullgen, Pangea Bio, Nurix Therapeutics, Jounce Therapeutics, Progenra, Cantex Pharmaceuticals, Exscientia, Kymera Therapeutics, Silverback Therapeutics, Relay Therapeutics, Recursion Pharmaceuticals, Plexium, Numerion Labs, Phenomic AI, insitro, NexImmune, Genetix Biotherapeutics, Beactica Therapeutics, ImmunoGenesis, Kronos Bio, CHARM Therapeutics, Citryll, PlantForm, Cedilla Therapeutics, Brightseed, Valence Labs, Schrodinger, ChemAxon, InSilico Medicine Cayman
- Keywords
- 2026: 383, 2025: 325, 2024: 246, 2023: 175, 2022: 150, 2021: 80, 2020: 20
- Competitors
- 44.80
- Ownership Status
- —
- Company Financing Status
- Privately Held (backing)
融资与估值
- Total Raised
- 383
- First Financing Date
- —
- First Financing Size
- 99
- First Financing Valuation
- vcolluru@enveda.com
- Last Financing Date
- 1.61%
- Last Financing Deal Type
- 04-Sep-2025
- Last Financing Size
- Later Stage VC
- Last Financing Valuation
- —
- Last Financing Status
- 1,161.00
- Last Known Valuation
- —
- Last Known Valuation Date
- Later Stage VC
- Last Known Valuation Deal Type
- —
- Valuation Estimate
- 04-Sep-2025
- Valuation Estimate Growth Rate
- computational biology, knowledge graphing, large language model, medicine discovery, natural products, novel drug discovery, small molecule therapeutics
- Active Investors
- Venture Capital-Backed
- # Active Investors
- 52%
- Acquirers
- Air Street Capital, Amino Collective, Baillie Gifford, Ben Cravatt, Bioverge, Catalio Capital Management, Christopher Gibson, Deviation Capital, Dimension (United States), Dimension Capital Management, FPV Ventures, Gaingels, Henry Kravis, Hummingbird Ventures, IA Ventures, JAZZ Venture Partners, Johnson & Johnson Innovation - JLABS, Kevin Lynch, Kevin Moore, Kinnevik, Level Ventures, Lifeforce Capital, Lingotto, Lux Capital, Martin Brenner, Matthew De Silva, Microsoft, Peakline Partners, Pieter Dorrestein, Possible Ventures, Premji Invest (US), Recursion Pharmaceuticals, Ryan Shenvi, Sanofi, Socium Ventures, The Nature Conservancy, True Ventures, Vertical Partners, Village Global, Wireframe Ventures, Yury Popov
团队与联系人
- Employees
- —
- Employee Growth %
- 2019
- Employee History
- —
- Primary Contact
- 529.98
- Primary Contact Title
- +1 (720) 594-6684
- Primary Contact Email
- Viswa Colluru
- Primary Contact Phone
- —
增长与经营
- Revenue
- 0.00%
- Revenue Growth %
- 38.95%
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- 236
- Size Multiple
- —
- Size Multiple % Change
- 1,161.00
- Size Multiple Change
- 0.00%
- Size Multiple Percentile
- 0.00x
- Majestic Referring Domains
- 28.48x
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- 2,731
- Success Probability Over Time – 1 Year
- 66%
- Success Probability Over Time – 3 Year
- 77%
- Success Probability Over Time – 5 Year
- Co-Founder, Chief Executive Officer & Board Member
记录来源：public.companies · 原始序号 #370 · 所有字段均按数据库原值展示。